GRAIL Investor Relations Material
Latest events
Q3 2024
GRAIL
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from GRAIL
Access all reports
GRAIL, Inc. is a biotechnology company specializing in the development of advanced technologies for early cancer detection. The company's primary product is the Galleri test, a multi-cancer early detection test designed to screen for a wide range of cancers, particularly those without current recommended screenings. In addition to Galleri, GRAIL is also working on diagnostic aids and minimal residual disease tests to assist in the detection and monitoring of cancer. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
GRAL
Country
πΊπΈ United States